MarginsXMarginsX
Home › Markets › Health Care › KZIA

Kazia Therapeutics Limited (KZIA)

KZIA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.60
-15.41% on the day
Market cap
$87.1M
Micro cap
Revenue · 2025
$28K
-98.2% on 2024
Net income · 2025
-$14.0M
-49290.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-06-30, https://www.sec.gov/Archives/edgar/data/1075880/000119312525272284/0001193125-25-272284-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-06-30. Converted from AUD at 1.4738 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerKZIA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryAustralia
IPO yearNot reported by the screener
SEC CIK0001075880

Financials · 2025

LineValue
Revenue$28K
Net income-$14.0M
Operating incomeNot in SEC XBRL data
Net margin-49290.5%
Operating marginOperating income not reported
Revenue growth-98.2%
Cash$2.9M
Total assets$4.1M
P/E (computed)Net income was not positive
P/S (computed)3055.4×

Reported in AUD; shown in US dollars.

Warning signs

Cash runway
3.9 months
4.3M AUD cash at June 30, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
Yes
20-F filed November 7, 2025
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"There is substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements for the fiscal year ended 30 June 2025 are issued."
20-F 2025-11-07
Cash and burn4.3M AUD cash; operating cash flow -3.3M AUD a quarter.Report 2025-06-30
Shares outstandingNo cover-page share count in XBRLNone on EDGAR
Reverse splits, 3 years2; latest 1-for-5 on 2025-04-17Source 2025-04-17
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 3 424B5 takedowns, 2 at the marketLatest 2026-08-31
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO Audit Pty Ltd, Sydney, AustraliaPCAOB Form AP 2025-11-12
Late filings, 12 months1 NT noticeNT 20-F 2026-11-02
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-06-30
42K AUD-20.7M AUD-13.3M AUD4.3M AUD396K AUD42K AUD20-F 2025-11-07
FY 2024
2024-06-30
2.3M AUD-26.8M AUD-9.6M AUD1.7M AUD634K AUD2.3M AUD20-F 2025-11-07
FY 2023
2023-06-30
0 AUD-20.5M AUD-15.2M AUD5.2M AUD1.8M AUD0 AUD20-F 2025-11-07
FY 2022
2022-06-30
0 AUD-25.0M AUD-22.8M AUD7.4M AUD1.8M AUD0 AUD20-F 2024-11-15
FY 2021
2021-06-30
15.2M AUD-8.4M AUD-9.1M AUD27.6M AUD0 AUD15.2M AUD20-F 2023-10-26
FY 2020
2020-06-30
Not filed-12.5M AUD-8.8M AUD8.8M AUDNo debt tagsNeeds four quarters20-F 2022-10-17
FY 2019
2019-06-30
Not filed-10.3M AUD-6.7M AUD5.4M AUDNo debt tagsNeeds four quarters20-F 2021-10-07
FY 2018
2018-06-30
119K AUD-6.0M AUD-8.7M AUD6.0M AUDNo debt tags119K AUD20-F 2019-10-21

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in AUD.

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-7.8%
1 month-17.7%
3 months-49.9%
Year to date-3.9%
1 year-9.2%
From 52-week high-60.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GNLXGenelux Corporation$1.92+2.95%$86.9M
NKTXNkarta Inc.$1.21+1.68%$86.8M
HURATuHURA Biosciences Inc.$1.33-4.32%$87.5M
RLYBRallybio Corporation$15.43-1.88%$86.4M
ANIXAnixa Biosciences Inc.$2.55-2.67%$88.6M
PMVPPMV Pharmaceuticals Inc.$1.19-6.30%$89.9M
RTSNRetension Pharmaceuticals Inc.$11.46-6.60%$90.3M
PLYXPolaryx Therapeutics Inc.$1.67-6.99%$83.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier